Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amur Minerals ( (GB:CRTX) ) has shared an announcement.
CRISM Therapeutics Corporation has received positive feedback from the MHRA on its clinical trial application for ChemoSeed, a novel chemotherapy delivery system for high-grade glioma. The MHRA’s advice eliminates the need for further preclinical toxicology studies, reducing costs and accelerating development. The company plans to submit its clinical trial application in the first half of 2025 and commence trials by the fourth quarter, with support from Aixial and potential grant funding assistance from Ryan LLC.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based innovative drug delivery company specializing in the localized delivery of chemotherapy drugs to improve the clinical performance of cancer treatments for solid tumors. Their lead product, ChemoSeed, is designed to be implanted directly into tumors or resection margins, particularly for high-grade glioma, to bypass the blood-brain barrier and deliver therapeutic concentrations of chemotherapy drugs effectively.
YTD Price Performance: -13.64%
Average Trading Volume: 24,533
Technical Sentiment Signal: Buy
Current Market Cap: £827K
For detailed information about CRTX stock, go to TipRanks’ Stock Analysis page.